| Title: | Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits |
| Journal: | eLife |
| Published: | 29 Mar 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36988189/ |
| DOI: | https://doi.org/10.7554/elife.80560 |
| Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
Publication 11252
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Causality between plasma triglyceride (TG) levels and atherosclerotic cardiovascular disease (ASCVD) risk remains controversial despite more than four decades of study and two recent landmark trials, STRENGTH, and REDUCE-IT. Further unclear is the association between TG levels and non-atherosclerotic diseases across organ systems.</p>
Methods: Here, we conducted a phenome-wide, two-sample Mendelian randomization (MR) analysis using inverse-variance weighted (IVW) regression to systematically infer the causal effects of plasma TG levels on 2600 disease traits in the European ancestry population of UK Biobank. For replication, we externally tested 221 nominally significant associations (p<0.05) in an independent cohort from FinnGen. To account for potential horizontal pleiotropy and the influence of invalid instrumental variables, we performed sensitivity analyses using MR-Egger regression, weighted median estimator, and MR-PRESSO. Finally, we used multivariable MR (MVMR) controlling for correlated lipid fractions to distinguish the independent effect of plasma TG levels.</p>
Results: Our results identified seven disease traits reaching Bonferroni-corrected significance in both the discovery (p<1.92 × 10-5) and replication analyses (p<2.26 × 10-4), suggesting a causal relationship between plasma TG levels and ASCVDs, including coronary artery disease (OR 1.33, 95% CI 1.24-1.43, p=2.47 × 10-13). We also identified 12 disease traits that were Bonferroni-significant in the discovery or replication analysis and at least nominally significant in the other analysis (p<0.05), identifying plasma TG levels as a novel potential risk factor for nine non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, p=1.17 × 10-5).</p>
Conclusions: Taking a phenome-wide, two-sample MR approach, we identified causal associations between plasma TG levels and 19 disease traits across organ systems. Our findings suggest unrealized drug repurposing opportunities or adverse effects related to approved and emerging TG-lowering agents, as well as mechanistic insights for future studies.</p>
Funding: RD is supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) (R35-GM124836) and the National Heart, Lung, and Blood Institute of the NIH (R01-HL139865 and R01-HL155915).</p>
13 Authors
- Joshua K Park
- Shantanu Bafna
- Iain S Forrest
- Áine Duffy
- Carla Marquez-Luna
- Ben O Petrazzini
- Ha My Vy
- Daniel M Jordan
- Marie Verbanck
- Jagat Narula
- Robert S Rosenson
- Ghislain Rocheleau
- Ron Do
1 Application
| Application ID | Title |
|---|---|
| 16218 | Dissecting the genetic and phenotypic architecture of cardiovascular disease |
Enabling scientific discoveries that improve human health